Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

– Absence of neurotoxicity of any grade in low-volume disease to-date –

– On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –

Read more at globenewswire.com